Evidence map›Paper›PMID 26347114›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2015

Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors.

H Boer, J H Proost, J Nuver, S Bunskoek, J Q Gietema, B M Geubels, R Altena, N Zwart, S F Oosting, J M Vonk and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
10.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Long-term toxicity of cisplatin in germ-cell tumor survivors.Annals of oncology : official journal of the European Society for Medical Oncology · 2017
    Pooled it
  4. Review
  5. Article
  6. Article
  7. 2025 Canadian Urological Association Expert Report: Muscle-invasive bladder cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025
    Article
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Testicular cancer survivorship: Long-term toxicity and management.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

H BoerDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
J H ProostDepartment of Hospital Pharmacy, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
J NuverDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
S BunskoekDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
J Q GietemaDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
B M GeubelsDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
R AltenaDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
N ZwartDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
S F OostingDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
J M VonkDepartment of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
J D LefrandtDepartment of Vascular Medicine, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
D R A UgesDepartment of Hospital Pharmacy, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
C MeijerDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
E G E de VriesDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
J A GietemaDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands j.a.gietema@umcg.nl.
University Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe success of cisplatin-based (Platinol, Bristol-Myers Squibb Company, New York, NY, USA) chemotherapy for testicular cancer comes at the price of long-term and late effects related to healthy tissue damage. We assessed and modelled serum platinum (Pt) decay after chemotherapy and determined relationships between long-term circulating Pt levels and known late effects. PATIENTS AND

methodsIn 99 testicular cancer survivors, treated with cisplatin-based chemotherapy, serum and 24-h urine samples were collected during follow-up (1-13 years after treatment). To build a population pharmacokinetic model, measured Pt data were simultaneously analysed, together with cisplatin dose, age, weight and height using the NONMEM software. Based on this model, area under the curve between 1 and 3 years after treatment (Pt AUC1-3 years) was calculated for each patient. Predicted long-term Pt exposure was related to renal function and to late effects of treatment assessed median 9 (3-15) years after chemotherapy.

resultsDecay of Pt was best described by a two-compartment model. Mean terminal T1/2 was 3.7 (range 2.5-5.2) years. Pt AUC1-3 years correlated with cumulative cisplatin dose, and creatinine clearance before and 1 year after treatment. Patients with paraesthesia had higher Pt AUC1-3 years (30.9 versus 27.0 µg/l month) compared with those without paraesthesia (P = 0.021). Patients with hypogonadism, elevated LDL-cholesterol levels or hypertension also had higher Pt AUC1-3 years.

conclusionsRenal function before and after cisplatin treatment is an important determinant of long-term Pt exposure. Known long-term effects of testicular cancer treatment, such as paraesthesia, hypogonadism, hypercholesterolaemia and hypertension, are associated with long-term circulating Pt exposure.

Indexed as

AdultCisplatinFollow-Up StudiesHumansHypercholesterolemiaHypertensionMaleMiddle AgedPlatinumTesticular NeoplasmsTreatment OutcomeYoung AdultCisplatinPlatinumBEPgerm cell cancerlong-term toxicitynephrotoxicityplatinum

Identifiers

PMID26347114
PMCPMC4621032
OpenAlexW2149160937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.